Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
14.9
%Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales546¥ millionYear on year +14.9%Progress 20.8%
Operating profit-310¥ million
Ordinary income-149¥ million
Net income attributable to owners of the parent-149¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share△1.56
Financial position at period-end
Total assets9,800¥ million
of which net assets 9,072 ¥ millionEquity ratio 92.5%vs. prior year-end +0.8pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueResearch Support Business ¥483,547 thousand (YoY +10.3%), Medical Business ¥63,152 thousand (YoY +69.2%)
Segment profitResearch Support Business ¥20,372 thousand, Medical Business ¥-13,166 thousand
Regional sales¥129,982 thousand, ¥250,116 thousand, ¥142,847 thousand, ¥23,753 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥2,629 million (YoY +17.7%)
Operating profit¥-630 million
Ordinary income¥-458 million
Net income¥-458 million
Annual Dividend Forecast¥0.00 → ¥0.00
Disclosure regarding the going concern assumption
The filing includes a material-event disclosure. It states that research and development expenses and clinical trial costs are incurred continuously ahead of revenue, resulting in recurring operating losses, and that events or conditions exist that raise substantial doubt about the going-concern assumption. At the same time, the company explains that it has ¥1,995 million in cash and deposits and ¥3,619 million in securities, indicating a stable financial base.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name None
Material subsequent eventsThe Board of Directors resolved on 1 July 2026 to conduct a third-party allotment, with CVI Investments, Inc. as the planned allottee. The filing states that the company plans to issue 2,932,000 common shares and 29,320 Series 18 stock acquisition rights on 16 July 2026.
Impairment lossNo applicable matters
Depreciation and amortization¥20,182 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNone (対象者：Not disclosed)
Issued Shares at Period-End98,079,891 shares
Treasury Shares at Period-End117,256 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥546 million (YoY +14.9%) |
| Operating profit | ¥-310 million |
| Ordinary income | ¥-149 million |
| Profit attributable to owners of the parent | ¥-149 million |
| Net income per share | △1.56 |
| Equity ratio | End of the current fiscal period 92.5 / End of previous period 91.7 |
| Total assets | ¥9,800 million |
| Net assets | ¥9,072 million |
| Full-year earnings forecast | Net Sales ¥2,629 million (YoY +17.7%) / Operating profit ¥-630 million / Ordinary income ¥-458 million / Net income ¥-458 million |
| Annual Dividend Forecast | ¥0.00 → ¥0.00 |
| Segment revenue | Research Support Business ¥483,547 thousand (YoY +10.3%), Medical Business ¥63,152 thousand (YoY +69.2%) |
| Segment profit | Research Support Business ¥20,372 thousand, Medical Business ¥-13,166 thousand |
| Regional sales | ¥129,982 thousand, ¥250,116 thousand, ¥142,847 thousand, ¥23,753 thousand |
| Depreciation and amortization | ¥20,182 thousand |
| Impairment loss | No applicable matters |
| Disclosure regarding the going concern assumption | The filing includes a material-event disclosure. It states that research and development expenses and clinical trial costs are incurred continuously ahead of revenue, resulting in recurring operating losses, and that events or conditions exist that raise substantial doubt about the going-concern assumption. At the same time, the company explains that it has ¥1,995 million in cash and deposits and ¥3,619 million in securities, indicating a stable financial base. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | The Board of Directors resolved on 1 July 2026 to conduct a third-party allotment, with CVI Investments, Inc. as the planned allottee. The filing states that the company plans to issue 2,932,000 common shares and 29,320 Series 18 stock acquisition rights on 16 July 2026. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 98,079,891 shares |
| Treasury Shares at Period-End | 117,256 shares |
Items this document does not state (11)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyOrders received and order backlogBreakdown of extraordinary income (loss)Factors Behind Changes in Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company reported higher revenue in its Research Support and Medical businesses and improved earnings in each segment, but did not specify the reasons for the increase in the consolidated operating loss.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.